BriaCell Therapeutics Corp. (CVE:BCT – Get Rating)'s stock price fell 3.8% during trading on Friday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Down 3.8 %
The firm has a market capitalization of C$168.68 million and a PE ratio of -28.19. The business's 50 day simple moving average is C$10.60 and its 200 day simple moving average is C$10.60. The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05.Get BriaCell Therapeutics alerts:
Insider Transactions at BriaCell Therapeutics
In other news, Director William Williams bought 27,272 shares of the stock in a transaction dated Thursday, July 14th. The stock was purchased at an average price of C$3.58 per share, for a total transaction of C$97,497.40. Following the acquisition, the director now owns 27,272 shares of the company's stock, valued at C$97,497.40.
About BriaCell Therapeutics(Get Rating)
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- Salesforce Stock Could Have Long Term Potential After Earnings
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.